Search
Dehydrocholic acid
go.drugbank.com/drugs/DB11622ApprovedThe use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.
Hexafluronium
go.drugbank.com/drugs/DB00941ApprovedHexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholineste...
Leptin
go.drugbank.com/drugs/DB05098InvestigationalAlthough leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite
Cyclophosphamide
go.drugbank.com/drugs/DB00531ApprovedInvestigationalPrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide.
Sodium phosphate, dibasic, unspecified form
go.drugbank.com/drugs/DB14504ApprovedMixtures: Up and Up Ready To Use EnemaHuman Interleukin 8
go.drugbank.com/drugs/DB16456InvestigationalInterleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).
V590
go.drugbank.com/drugs/DB16437ExperimentalBy teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583].
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalPurified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S.. … It contains an amino acid sequence identical to the naturally occurring hormone consisting of 27 amino acids [FDA Label] that supports α-helical formation [A32275].
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalThe reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively.